Key Takeaways
- • Benchmark raised its price target on Unicycive Therapeutics (NASDAQ: UNCY) to $18 from $15 while maintaining a Speculative Buy rating, reflecting updated share count and weighted average cost of capital (WACC) assumptions rather than revenue estimate changes.
- • The FDA assigned a PDUFA date of June 29, 2026, for oxylanthanum carbonate, Unicycive's lead candidate for hyperphosphatemia treatment in chronic kidney disease dialysis patients, with the agency accepting the company's resubmitted New Drug Application in January 2026.
- • Unicycive maintains a strong balance sheet with $57.1 million in cash, cash equivalents, and short-term investments as of May 11, 2026, sufficient to fund operations through 2027 and support regulatory approval and commercialization preparations; the company carries minimal debt with a debt-to-equity ratio of 0.02 and current ratio of 2.4.
- • The stock currently trades at $7.76, up 7.65% over the past week, though InvestingPro analysis suggests shares may be overvalued relative to fair value estimates despite Benchmark's price target increase.
- • Benchmark's valuation excludes potential upside from UNI-494, an acute kidney injury candidate targeting delayed graft function in kidney transplant patients, providing optionality beyond the primary oxylanthanum carbonate commercialization opportunity.
Summary
Benchmark Capital raised its price target on Unicycive Therapeutics to $18 per share from $15, maintaining a Speculative Buy rating on the clinical-stage biopharmaceutical company. The price target adjustment reflects updated modeling assumptions around share count and cost of capital, rather than changes to forward revenue estimates for the company's pipeline. At current trading levels of $7.76, the stock has appreciated 7.65% over the past week, though valuation analysis suggests the shares may trade above intrinsic value estimates.
The price target revision comes as Unicycive approaches a critical regulatory milestone. The FDA accepted the company's resubmitted New Drug Application for oxylanthanum carbonate in January 2026, assigning a PDUFA decision date of June 29, 2026. Oxylanthanum carbonate targets hyperphosphatemia in patients with chronic kidney disease on dialysis—a significant indication within nephrology. The company is actively preparing for potential commercialization, including establishing patient reimbursement infrastructure ahead of an anticipated launch window.
Unicycive's financial position provides operational flexibility through the regulatory process and early commercialization phase. As of May 11, 2026, the company held $57.1 million in cash, cash equivalents, and short-term investments, with management guidance that this capital will sustain operations into 2027. The balance sheet demonstrates financial discipline, with a minimal debt-to-equity ratio of 0.02 and a healthy current ratio of 2.4, indicating the company carries more cash than debt and maintains adequate liquidity to cover near-term obligations.
Beyond oxylanthanum carbonate, Benchmark's valuation excludes upside potential from UNI-494, a drug candidate in development for acute kidney injury with a specific focus on delayed graft function in kidney transplant recipients. This pipeline optionality provides additional value creation potential if clinical development progresses successfully. The company's first-quarter 2026 financial results aligned with market expectations and continue to track toward the June 29 FDA decision date. Analyst price targets across Wall Street range from $30 to $105 per share, reflecting significant uncertainty around the regulatory outcome and commercial execution.
The price target revision comes as Unicycive approaches a critical regulatory milestone. The FDA accepted the company's resubmitted New Drug Application for oxylanthanum carbonate in January 2026, assigning a PDUFA decision date of June 29, 2026. Oxylanthanum carbonate targets hyperphosphatemia in patients with chronic kidney disease on dialysis—a significant indication within nephrology. The company is actively preparing for potential commercialization, including establishing patient reimbursement infrastructure ahead of an anticipated launch window.
Unicycive's financial position provides operational flexibility through the regulatory process and early commercialization phase. As of May 11, 2026, the company held $57.1 million in cash, cash equivalents, and short-term investments, with management guidance that this capital will sustain operations into 2027. The balance sheet demonstrates financial discipline, with a minimal debt-to-equity ratio of 0.02 and a healthy current ratio of 2.4, indicating the company carries more cash than debt and maintains adequate liquidity to cover near-term obligations.
Beyond oxylanthanum carbonate, Benchmark's valuation excludes upside potential from UNI-494, a drug candidate in development for acute kidney injury with a specific focus on delayed graft function in kidney transplant recipients. This pipeline optionality provides additional value creation potential if clinical development progresses successfully. The company's first-quarter 2026 financial results aligned with market expectations and continue to track toward the June 29 FDA decision date. Analyst price targets across Wall Street range from $30 to $105 per share, reflecting significant uncertainty around the regulatory outcome and commercial execution.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.